SEATTLE--(BUSINESS WIRE)--Dendreon Corporation (NASDAQ:DNDN) today announced the Centers for Medicare and Medicaid Services (CMS) updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE® (sipuleucel-T). With this decision, the coverage of PROVENGE is now consistent with all other infused biologics.
